Ionis Pharmaceut

Citi analyst Eric Joseph reaffirms a $100 price target and calls the recent share declines at Ionis Pharmaceuticals overdone. The drug Tryngolza is outperforming expectations and the peak-sales forecast has been raised to over €1.8 billion. The company’s shift to a fully commercial biotech is supported by a pipeline with five upcoming phase-3 readouts in 2026. Focus remains on RNA technology and commercial expansion. » More on finanzen.net

Shares of Ionis Pharmaceuticals fell to a new 52-week low of $50.00, about 35% below the level at the start of the year; market capitalization is roughly $8.45 billion. Falling prices reflect both broader market conditions and company-specific issues, notably disappointing study data for the drug Pelacarsen. Several analysts subsequently cut their price targets and removed expected milestone and licensing payments, though some maintained buy recommendations. » More on de.investing.com

At the Wells Fargo Healthcare Conference Ionis highlighted commercial progress: two in-house FDA approvals in 2024 (TRYNGALZA, ZANVASTRO) and an upcoming GSK approval for chronic hepatitis B. The TRYNGALZA launch is outperforming expectations with strong prescription momentum, payer acceptance and a U.S. revenue potential of over $3 billion. At the same time, Pelacarsen (Lp(a)) and Eplontersen (ATTR cardiomyopathy) missed primary endpoints, increasing pipeline risk; however, Eplontersen monotherapy subgroups still show positive signals. Ionis is advancing next‑gen candidates such as ION775 and remains committed to long‑term revenue targets for TRYNGALZA and DAWNZERA. » More on de.investing.com